Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Vor looks to answer the Car-T question
Can the company add a Car-T string to its stem cell transplant bow?
Make or break time for Caribou
The company’s matching strategy for CB-010 will soon be put to the test.
How to be different in in vivo Car-T
After Astra's EsoBiotec takeover the battle for uniqueness begins.
Astra gives in vivo Car-T its biggest endorsement
The company buys Belgium’s EsoBiotec for $425m.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
